Ratings Vext Science, Inc.

Equities

VEXT

CA9255401064

Healthcare Facilities & Services

Market Closed - Canadian Securities Exchange Other stock markets 19:00:25 29/11/2024 GMT			5-day change	1st Jan Change
0.2000 ^CAD	-.--%		+5.26%	-31.03%

11-21	Vext Science, Inc., Q3 2024 Earnings Call, Nov 21, 2024
11-21	Vext Science, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI

Summary: Vext Science, Inc.

Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Highlights: Vext Science, Inc.

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
Given the positive cash flows generated by its business, the company's valuation level is an asset.
For several months, analysts have been revising their EPS estimates roughly upwards.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses: Vext Science, Inc.

The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
One of the major weak points of the company is its financial situation.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings Chart: Vext Science, Inc.

Source: Surperformance

Sector Comparison:

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Composite Valuation	Capi. ($)
VEXT SCIENCE, INC.	-	35.32M
ORGANIGRAM HOLDINGS INC.	-	166M
ASCEND WELLNESS HOLDINGS, INC.	-	85.83M
AYR WELLNESS INC.	-	78.04M
JUSHI HOLDINGS INC.	-	68.45M
THE CANNABIST COMPANY HOLDINGS INC.	-	52.99M
Average	-	81.08M
Weighted average by Cap.	-

See all sector ratings

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality